Xu, Fengyu Huang, Mengqi Chen, Qingyong Niu, Yi Hu, Yuhang Hu, Ping Chen, Ding He, Chi Huang, Kang Zeng, Zhu
...
Published in
Cancer research
Gemcitabine (GEM) resistance is a major challenge for chemotherapy of pancreatic cancer (PC). Previous studies have reported on the role of lncRNA in tumorigenesis of PC, however, the involvement of lncRNA in the development of GEM resistance of PC remains unclear. In the present study, we demonstrated that the antisense RNA1 of HIF-1α (HIF1A-AS1) ...
Yang, Junyu Gao, Chong Liu, Miao Liu, Yao-Chung Kwon, Junsu Qi, Jun Tian, Xi Stein, Alicia Liu, Yanjing V Kong, Nikki R
...
Published in
Cancer research
Oncofetal protein SALL4 is critical for cancer cell survival. Targeting SALL4, however, is only applicable in a fraction of cancer patients that are positive for this gene. To overcome this limitation, we propose to induce a cancer vulnerability by engineering a partial dependency upon SALL4. Following exogenous expression of SALL4, SALL4-negative ...
Sanjiv, Kumar Calderón-Montaño, José Manuel Pham, Therese M Erkers, Tom Tsuber, Viktoriia Almlöf, Ingrid Höglund, Andreas Heshmati, Yaser Seashore-Ludlow, Brinton Nagesh Danda, Akhilesh
...
Published in
Cancer research
Acute myeloid leukemia (AML) is an aggressive hematological malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested to drive leukemogenesis and is thus a potential novel target for treating AML. MTH1 prevents incorporation of oxidized nucleotides into the DNA to maintain genome integrity and is upregulate...
Evans, Kurt W Yuca, Erkan Scott, Stephen S Zhao, Ming Paez Arango, Natalia Cruz Pico, Christian X Saridogan, Turcin Shariati, Maryam Class, Caleb A Bristow, Christopher A
...
Published in
Cancer research
Oxidative phosphorylation (OXPHOS) is an active metabolic pathway in many cancers. RNA from pre-treatment biopsies from patients with triple negative breast cancer (TNBC) who received neoadjuvant chemotherapy demonstrated that the top canonical pathway associated with worse outcome was higher expression of an OXPHOS signature. In multiple TNBC pati...
Cappello, Sabrina Sung, Hsu-Min Ickes, Christian Gibhardt, Christine S Vultur, Adina Bhat, Hilal Hu, Zhongwen Brafford, Patricia Denger, Andreas Stejerean-Todoran, Ioana
...
Published in
Cancer research
Despite impressive advances in melanoma-directed immunotherapies, resistance is common and many patients still succumb to metastatic disease. In this context, harnessing natural killer (NK) cells, which have thus far been sidelined in the development of melanoma immunotherapy, could provide therapeutic benefits for cancer treatment. To identify mol...
Liu, Jianglan Rebecca, Vito W Kossenkov, Andrew V Connelly, Thomas Liu, Qin Gutierrez, Alexis Xiao, Min Li, Ling Zhang, Gao Samarkina, Anastasia
...
Published in
Cancer research
Metastatic melanoma is challenging to clinically address. Although standard of care targeted therapy has high response rates in patients with BRAF-mutant melanoma, therapy relapse occurs in most cases. Intrinsically resistant melanoma cells drive therapy resistance and display molecular and biologic properties akin to neural crest-like stem cells (...
Wang, Long Hensch, Nicole R Bondra, Kathryn Sreenivas, Prethish Zhao, Xiang R Chen, Jiangfei Moreno Campos, Rodrigo Baxi, Kunal Vaseva, Angelina V Sunkel, Benjamin D
...
Published in
Cancer research
Ionizing radiation (IR) and chemotherapy are mainstays of treatment for patients with rhabdomyosarcoma (RMS), yet the molecular mechanisms that underlie the success or failure of radiotherapy remain unclear. The transcriptional repressor SNAI2 was previously identified as a key regulator of IR sensitivity in normal and malignant stem cells through ...
McDonald, James I Diab, Noor Arthofer, Elisa Hadley, Melissa Kanholm, Tomas Rentia, Uzma Gomez, Stephanie Yu, Angela Grundy, Erin E Cox, Olivia
...
Published in
Cancer research
Epithelial ovarian carcinomas (OC) are particularly deadly due to intratumoral heterogeneity, resistance to standard-of-care therapies, and poor response to alternative treatments such as immunotherapy. Targeting the OC epigenome with DNA methyltransferase inhibitors (DNMTi) or histone deacetylase inhibitors (HDACi) increases immune signaling and r...
Zhao, Zibo Szczepanski, Aileen P. Tsuboyama, Natsumi Abdala-Valencia, Hiam Goo, Young Ah Singer, Benjamin D. Bartom, Elizabeth T. Yue, Feng Wang, Lu
Published in
Cancer research
Abnormalities in genetic and epigenetic modifications can lead to drastic changes in gene expression profiles that are associated with various cancer types. Small cell lung cancer (SCLC) is an aggressive and deadly form of lung cancer with limited effective therapies currently available. By utilizing a genome-wide CRISPR-Cas9 dropout screen in SCLC...
Yenerall, Paul Kollipara, Rahul K. Avila, Kimberley Peyton, Michael Eide, Christopher A. Bottomly, Daniel McWeeney, Shannon K. Liu, Yan Westover, Kenneth D. Druker, Brian J.
...
Published in
Cancer research
Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). Here we optimized and leveraged this property to identify drug resistance mutations, developing a technique we term LentiMutate. This techn...
